EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy

Heng Dong, Zhengguo Zhang, Mengjie Ni, Xiaoyun Xu, Yifeng Luo, Yaru Wang, Haiyun Zhang, Jianxiang Chen

Current Treatment Options in Oncology · 2024

DOI: 10.1007/s11864-024-01246-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2024. Verfasst von Heng Dong und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, 311121,…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Molecular Targeted Therapy, Immunotherapy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: Hepatocellular carcinoma (HCC) is a common type of tumor worldwide. The development of systemic treatment of advanced HCC has remained stagnant for a considerable period. During the last years, a series of new treatment regimens based on the combination of immunotherapeutic drugs and targeted drugs have been gradually developed, increased the objective response rate (ORR), overall survival (OS), and progression free survival (PFS) of HCC patients. Among the different combination therapy groups, atezolizumab plus bevacizumab and sintilimab plus IBI-305 seem to have unique advantages, while head-to-head comparisons are still needed. A comprehensive understanding of the developments, the ongoing clinical trials and the mechanisms of combination of immunotherapy and targeted therapy might lead to the development of new combination strategies and solving current challenges such as the molecular biomarkers, the clinical administration order of drugs and the second-line treatments after combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMolecular Targeted TherapyImmunotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansCombined Modality TherapyNeoplasm StagingTreatment OutcomeDisease ManagementClinical Trials as TopicImmune Checkpoint InhibitorsBiomarkers, Tumor

Stichwörter der Autor:innen

Combination therapyHepatocellular carcinomaImmunotherapyTargeted drugs

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • School of Pharmacy and Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, 311121, People's Republic of China.
  • Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of…
  • School of Pharmacy and Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, 311121, People's Republic of China. chenjx@hznu.edu.cn.
  • Laboratory of Cancer Genomics, Division of Cellular and Molecular Research, National Cancer Centre, Singapore, 169610, Singapore. chenjx@hznu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Dong, H., Zhang, Z., Ni, M., Xu, X., Luo, Y., Wang, Y., Zhang, H., & Chen, J. (2024). The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-024-01246-9

Vancouver

Dong H, Zhang Z, Ni M, Xu X, Luo Y, Wang Y, et al. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy. Current Treatment Options in Oncology. 2024. doi:10.1007/s11864-024-01246-9

BibTeX
@article{Dong2024,
  author = {Dong, Heng and Zhang, Zhengguo and Ni, Mengjie and Xu, Xiaoyun and Luo, Yifeng and Wang, Yaru and Zhang, Haiyun and Chen, Jianxiang},
  title = {The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  doi = {10.1007/s11864-024-01246-9}
}
Kostenlos starten →